Efficacy and safety of piroxicam patch versus piroxicam cream in patients with lumbar osteoarthritis: A randomized, placebo-controlled study

Arzneimittel-Forschung/Drug Research

Volumn 59, Issue 8, 2009, Pages 403-409

  Allegrini, Alessandro ^a   Nuzzo, Loredana ^a   Pavone, Daniele ^a   Tavella Scaringi, Andrea ^a   Giangreco, Daniela ^a   Bucci, Marco ^a   Toniato, Elena ^a   Mezzetti, Andrea ^a   Martinotti, Stefano ^a   Comuzio, Sergio ^b   Di Grigoli, Maurizio ^b   Bonani, Stefano ^c  

^a UNIVERSITY OF CHIETI   (Italy)

^b Bouty SpA   (Italy)

^c Segix Italia S r L   (Italy)

Author keywords

CAS 36322 90 4; Lumbar osteoarthritis; Non steroidal anti inflammatory drug (NSAID), patch; Piroxicam, efficacy, safety

Indexed keywords

PIROXICAM; PLACEBO;

ADULT; AGED; ANALGESIA; APPLICATION SITE PRURITUS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; CYSTITIS; DAILY LIFE ACTIVITY; DISABILITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG SAFETY; ERYTHEMA; FUNCTIONAL DISEASE; HUMAN; INFLUENZA; LUMBAR SPONDYLOSIS; MAJOR CLINICAL STUDY; MUSCLE ISOMETRIC CONTRACTION; PAIN; PASSIVE MOVEMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; SORE THROAT; SPONDYLOSIS; TRANSDERMAL PATCH; VISUAL ANALOG SCALE;

EID: 69249137797     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296415     Document Type: Article

References (14)

1. Zizic TM, Sutton JD, Stevens MB. Long term experience with piroxicam in osteoarthritis. Semin Arthritis Rheum. 1985;14:14-19 (Pubitemid 15137613)
2. Meisel AD. Clinical benefits and comparative safety of piroxicam. Am J Med 1986;81 Suppl 5B:15-21.
3. Rasetti-Escargueil C, Grangé V. Pharmacokinetic profiles of two tablet formulations of piroxicam. Int J Pharm. 2005;295:129-134 (Pubitemid 40558796)
4. Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ. 2004;329:324. (Pubitemid 39062301)
5. Huskisson EC. Measurement of pain. J Rheumatol. 1982;9:768-769
6. nd WMA General Assembly, Edinburgh (Scotland); October 2000.
7. The European Agency for the Evaluation of Medicinal Products. Note for Guidance on Good Clinical Practice. July 2002 CPMP/ICH/135/95.
8. Lee JS, Hobden E, Stiell IG, Wells GA. Clinically important change in the visual analog scale after adequate pain control. Acad Emerg Med. 2003;10(10):1128-1130 (Pubitemid 37205689)
9. Cepeda MS, Africano JM, Polo R, Alcala R, Carr DB. What decline in pain intensity is meaningful to patients with acute pain? Pain. 2003;105(1-2):151-157
10. Guidance for Industry. Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. U.S. Department of Health and Human Services, Food and Drug Administration; May 1998.
11. The European Agency for the Evaluation of Medicinal Products. Points to consider on switching between superiority and non-inferiority. London, 27 July 2000 CPMP/EWP/482/99.
12. The European Agency for the Evaluation of Medicinal Products. Note for guidance on statistical principles for clinical trials. September 1998 CPMP/ICH/363/96.
13. Newcombe RG. Interval estimation for the difference between different proportions: comparison of eleven method. Statist Med. 1998;17:873-890
14. Newcombe RG, Altman DG. Proportions and their differences. In: Altman DG, D. Machin, Bryant TN, Gardner MJ, editors. Statistics with Confidence. 2nd ed. London: BMJ Books; 2000.